U.S., June 28 -- ClinicalTrials.gov registry received information related to the study (NCT07041203) titled 'Extended-release Sodium Oxybate (Lumryz) in Spasmodic Dysphonia and Voice Tremor' on June 04.
Brief Summary: Using a comprehensive approach of clinico-behavioral testing and neuroimaging, the researchers will examine the clinical effects of the extended-release formulation of sodium oxybate on voice symptoms in spasmodic dysphonia in an open-label, proof-of-concept, dose-finding study.
Study Start Date: Aug. 01
Study Type: INTERVENTIONAL
Condition:
Spasmodic Dysphonia
Laryngeal Dystonia
Voice Tremor
Intervention:
DRUG: sodium oxybate
Oral administration of sodium oxybate (1.5g, 2.0g, 2.5g, 3.0g)
Recruitment Status: NOT_YET_R...